

February, 26 2006

**MediWound, Developer Of A Unique Medicament For The Treatment Of Second And Third Degree Burns, Is Entering Phase III Clinical Trials**

**MediWound**, an Israeli biotechnology company, the developer of a unique medicament for the initial treatment of second and third degree burns, reports it has commenced Phase III clinical trials.

The Company carries out additional clinical trials (conclusion of Phase II) at leading centers in the US during year 2006. Recently, the Company's burn care product was granted an Orphan Drug Status. This status establishes exclusivity of sales in EC and the US for 10 and 7 years respectively from the time that the drug will be approved for marketing as well as an expedited regulatory approval in the EC and the US.

DGD (Debrase<sup>®</sup> Gel Dressing), **MediWound's** leading product, is a debriding agent that removes damaged tissues fast, safely and selectively thus initiating the wound's healing process. This innovative Minimal Invasive Treatment Modality presents an alternative to lengthy, complex and dangerous surgical procedures.

The clinical effectiveness of the drug developed by **MediWound** has been demonstrated in over 400 patients throughout approximately 20 leading medical centers in Europe, US, Asia and Israel.

According to Prof. Marian Gorecki, present CEO of **MediWound** and formerly BTG's entrepreneur, the technology at the heart of DGD answers the unmet need to remove fast, safely and selectively damaged tissues without resorting to dangerous and traumatic excisional surgical and unnecessary sacrifice of healthy tissues. This ability spares patients significant suffering involved in surgery, expedites the burn's healing, and eliminates needless scaring and substantial skin graft harvesting. Prof. Gorecki stated that the Company is underway to expand the technological applications for indications such as products designated to treat minor burns and chronic wounds.

Founded in 2001, **MediWound** is backed by Clal Biotechnology Industries Ltd., Israel's largest life-science investment company, currently the Company's major shareholder (80%). Headquartered at Yavneh's industrial zone in an advanced manufacturing facility, the Company employs 20 employees and has secured \$14 million to date. For more information please visit [www.mediwound.co.il](http://www.mediwound.co.il)

**About Clal Biotech Industries (CBI)**

Clal Biotech Industries was established in 1998 and has since become the largest life science investor in Israel and among the top 10 in Europe. CBI has brought together an experienced management team encompassing outstanding scientists, business managers and investment professionals, capable of targeting and managing companies with innovative technologies and products. For more information about CBI please visit [www.cbi.co.il](http://www.cbi.co.il)

**For more information please contact:**

Avida Landau – Director of Intl. Communications  
Idan Corporate Image Communication  
[avida@idancom.com](mailto:avida@idancom.com)  
Office: +972-9-9514666  
Mobile: +972-50-9369478